AI assistant
Sending…
ATOSSA THERAPEUTICS, INC. — Director's Dealing 2024
Jul 1, 2024
34113_dirs_2024-07-01_63916bbe-321e-480a-a788-1d0e9f6bef28.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ATOSSA THERAPEUTICS, INC. (ATOS)
CIK: 0001488039
Period of Report: 2024-06-27
Reporting Person: Galli Stephen J (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-06-27 | Stock Option (right to buy) | $1.05 | A | 125000 | Acquired | 2034-06-27 | Common Stock (125000) | Direct |
Footnotes
F1: The options shall vest on a quarterly basis over 12 months following June 27, 2024, subject to the Reporting Person's continued service through each applicable vesting date. The options were issued at approximately 9:30 a.m. (ET) on June 27, 2024 with an exercise price of $1.05, representing the most recently reported closing stock price on June 26, 2024.
More from ATOSSA THERAPEUTICS, INC.
Regulatory Filings
2026
May 8
Interim / Quarterly Report
2026
May 8
Regulatory Filings
2026
May 8
Regulatory Filings
2026
Apr 16
Director's Dealing
2026
Mar 31
Annual Report
2026
Mar 25
Regulatory Filings
2026
Mar 20
Regulatory Filings
2026
Feb 20
Regulatory Filings
2026
Feb 17
Regulatory Filings
2026
Feb 11